0.411
-0.02 (-5.60%)
| Previous Close | 0.435 |
| Open | 0.461 |
| Volume | 638,411 |
| Avg. Volume (3M) | 6,482,756 |
| Market Cap | 114,175,024 |
| Price / Earnings (Forward) | 35.84 |
| Price / Sales | 51.64 |
| Price / Book | 5.01 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Operating Margin (TTM) | -4,484.33% |
| Diluted EPS (TTM) | -0.690 |
| Total Debt/Equity (MRQ) | 228.93% |
| Current Ratio (MRQ) | 3.68 |
| Operating Cash Flow (TTM) | -99.38 M |
| Levered Free Cash Flow (TTM) | -67.40 M |
| Return on Assets (TTM) | -42.82% |
| Return on Equity (TTM) | -249.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Humacyte, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.50 |
Select this tab to load the latest available analysis.
|
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 20.16% |
| % Held by Institutions | 40.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Antipodes Partners Ltd | 30 Jun 2026 | 10,103,647 |
| Great Point Partners I Lp | 30 Jun 2026 | 3,750,000 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |